Biomarin Pharmaceutical (BMRN) Long-Term Investments (2009 - 2025)

Biomarin Pharmaceutical has disclosed Long-Term Investments across 17 years of filings, most recently posting $492.2 million for Q4 2025.

• Quarterly Long-Term Investments fell 5.56% year-over-year to $492.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $492.2 million (down 5.56% YoY) and the FY2025 annual result came in at $492.2 million, down 5.56% from the prior year.
• Long-Term Investments retreated to $492.2 million in Q4 2025, from $512.9 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $620.6 million in Q1 2024 and troughed at $321.1 million in Q1 2021.
• A 5-year average of $469.7 million and a median of $499.5 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments tumbled 34.26% — and 2023, when it jumped 83.06%.
• Tracing BMRN's Long-Term Investments over 5 years: stood at $507.8 million in 2021, then slumped by 34.26% to $333.8 million in 2022, then soared by 83.06% to $611.1 million in 2023, then fell by 14.71% to $521.2 million in 2024, then declined by 5.56% to $492.2 million in 2025.
• Business Quant data shows BMRN's Long-Term Investments at $492.2 million in Q4 2025, $512.9 million in Q3 2025, and $508.6 million in Q2 2025.